ORIC Pharmaceuticals Inc
ORIC
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.25B
Close$
$0.39
96.8% downside
Current Fair Value
96.8% downsideOvervalued by 96.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.25 Billion |
|---|---|
| Enterprise Value | $1.21 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.47 |
| Beta | 0.99 |
| Outstanding Shares | 108,012,388 |
Return
| Return on Equity | -36.81% |
|---|---|
| Return on Assets | -34.68% |
| Return on Invested Capital | -39.69% |
Valuation & Multiples
| P/E Ratio | -8.92 |
|---|---|
| PEG | -63.12 |
| Price to Sales | - |
| Price to Book Ratio | 4.01 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.96 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2756▼ 65.06% |
|---|---|
| Total Calls | 414,700▲ 410.09% |
| Total Puts | 114,300▲ 51.79% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 115.02%▲ 1.86% |
|---|---|
| Total Invested | $1.34B▼ 10.93% |
| Investors Holding | 189▲ 4.00% |
ESG Score
No data
About ORIC Pharmaceuticals Inc
CEO: Jacob Chacko